This edition presents the views and insights from three of the world's foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the psoriasis market. Topics covered include opinions regarding Novartis' announcement of additional positive data from the head-to-head CLARITY study, evaluating Cosentyx (secukinumab) against Stelara (ustekinumab; Janssen) in treating adults with moderate to severe plaque psoriasis; insights on UCB's positive Phase IIb BE ABLE 2 extension trial of bimekizumab; as well as AbbVie's announcement that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the IL-23 inhibitor Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis.
Business Questions:
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved